Home > Healthcare & Medical Devices > Intragastric Balloon Market

Intragastric Balloon Market Size By Product (Single Intragastric Balloon, Dual Intragastric Balloon, Triple Intragastric Balloon), By Filling Material (Saline-filled, Gas-filled), By End-use (Hospitals, Ambulatory Surgical Centers, Clinics), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2022 – 2028

  • Report ID: GMI1173
  • Published Date: Jan 2022
  • Report Format: PDF

Industry Trends

Intragastric Balloon Market size exceeded USD 34 million in 2021 and is anticipated to grow at CAGR of over 13.4% between 2022 to 2028. The market growth is attributed to the low treatment cost as compared to other treatments coupled with high prevalence of obesity. Adoption of sedentary lifestyle as well as unhealthy diet & alcohol abuse are some of the major causes of growing incidence of obesity.
 

Intragastric Balloon Market Overview

Get more details on this report - Request Free Sample PDF
 

The spread of COVID-19 pandemic across the globe has impacted the market negatively. Individuals with an underlying condition including obesity are at high risk during the COVID-19 pandemic. For instance, in March 2021, as per the Center for Disease Control and Prevention (CDC), nearly 30.2% of the total COVID-19 hospitalizations were attributed to obesity. Similarly, increase in number of COVID-19 infections across several countries has resulted in delaying or postponing the non-essential surgical procedures including gastric balloon procedures. Also, various companies witnessed a significant dip in the sales of gastric balloon products in 2020 due to the COVID-19 pandemic.
 

Technological advances in intragastric balloon providing effective treatment is expected to boost the market expansion during the forecast period. Advances to reduce undesirable effects such as gastric erosion, ulceration and vomiting is poised to foster the business growth. Furthermore, gastric balloons are placed into the stomach through mouth and normally takes not more than half hour, during which a patient is under mild sedation. The balloons are designed to be in place for around half year duration.
 

Lack of reimbursement may slow down the intragastric balloon market progression

Intragastric balloon treatment is a relatively a new technology available for obesity management. Lack of reimbursement for such procedures in most of the countries can potentially restrain the market demand during the forecast period. Generally, health insurance plans have eligibility criteria of body mass index (BMI) 35 or 45 for providing reimbursement for weight loss procedures. However, patients are eligible for intragastric balloon treatment at BMI 27 and are thus not reimbursed. Additionally, most countries treat intragastric balloon as a primary procedure which is in the investigational stage. The procedure is not listed for reimbursement in Medicare and Medicaid (CMC) in U.S. with similar scenario existing in Canada, Australia, and other countries of Asia and Europe regions.
 

Single intragastric balloons will exhibit sluggish industry growth

Intragastric Balloon Market Size

Get more details on this report - Request Free Sample PDF
 

The single intragastric balloon segment accounted for USD 23.2 million in 2021 led by the rising awareness coupled with increasing usage of non-invasive procedures. Also, increasing number of obese patients worldwide and improved product design will accelerate the segment growth during the forecast period. Furthermore, various technological advances for improving patient outcomes and development of next generation intragastric balloon will spur the industry expansion in the coming years. However, with the introduction of dual and triple intragastric balloons, single intragastric balloons will exhibit sluggish the industry progression during the forecast period.
 

Wide usage and advantages associated with saline-filled intragastric balloon to propel the segment expansion

Saline-filled balloon segment held more than 63% of the market share in 2021 impelled by the advantages associated with saline-filled intragastric balloon. The advantages include ability to reduce weight more effectively and quick detection of silicone balloon deflation due to methylene blue dye. The dye helps in identifying if the balloon is ruptured. This non-invasive and non-pharmacological approach helps in reduction of around 15 to 25 kg weight.
 

Hospital segment dominated the market value

The hospitals segment accounted for 35.5% of revenue share in 2021 owing to the growing disease burden including obesity coupled with increasing healthcare investments worldwide. Moreover, government policies for implementation of high-quality patient care will attract large number of patients in hospitals to seek treatments. Also, new clinical trials conducted in multi-specialty hospitals will provide opportunities to the patients to explore new experimental therapies, thereby augmenting the segment value.
 

Rising prevalence of obesity coupled with high acceptance of non-surgical treatments in North America region will stimulate the market revenue

Global Intragastric Balloon Market

Get more details on this report - Request Free Sample PDF
 

North America intragastric balloon market size was over USD 12.5 million in 2021 and is predicted to witness 12.1% growth rate through 2028. The key factors driving the regional growth includes rising prevalence of obesity coupled with high adoption of non-surgical treatments. For instance, according to 2017 obesity update by the Organization for Economic Co-operation and Development (OECD), about 47% of the total population in U.S. is suffering from obesity. Similarly, according to Canadian Institute for Health Information, obesity is one of the major health issues in Canada, affecting about 1 in 5 Canadian adults. Thus, as number of obese patients will increase in U.S. and Canada, the demand for obesity treatment will also increase, thereby leading to industry demand of intragastric balloon in North America region.
 

Growth strategies of market players are focused on increasing the customer base

Few of the notable companies operating in the market are Allurion Technologies, Districlass Medical, Apollo Endosurgery, Helioscopie Medical Implants, Medsil, ReShape Medical, Silimed and Spatz. These leaders adopt strategies such as novel product launch, mergers and acquisitions to influence business in industry of intragastric balloon.
 

The intragastric balloon market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028, for the following segments

Market, By Product

  • Single intragastric balloon
  • Dual intragastric balloon
  • Triple intragastric balloon

Market, By Filling Material

  • Saline-filled balloon
  • Gas-filled balloon

Market, By End-use

  • Hospitals
  • Ambulatory surgical centers
  • Clinics

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

The global market size of intragastric balloon surpassed $34 million in 2021 and is expected to record a strong CAGR of more than 13.4% during the forecast period of 2022-2028.

The single intragastric balloon segment accounted for $23.2 million in 2021 as the demand for non-invasive surgeries is growing and several technological advancements are being introduced in these products to help obese patients better manage their condition.

Saline-filled intragastric balloons occupied over 63% of the market share in 2021 as there are several advantages of using these balloons, such as ability to reduce weight more effectively and faster detection of the silicone balloon deflation due to the presence of methylene blue dye.

Hospitals accounted for nearly 35.5% of revenue share in 2021 as new clinical trials are being conducted to help patients diagnosed with obesity explore various experimental therapies to better manage their ailment.

Notable organizations, such as Allurion Technologies, Medsil, Districlass Medical, Apollo Endosurgery, Helioscopie Medical Implants, and Silimed Inc., among many others, are positively influencing the global market forecast.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2021
  • Companies covered: 11
  • Tables & Figures: 101
  • Countries covered: 18
  • Pages: 120

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount